Sat, Jul 12, 2014, 5:40 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

GENTA INC Message Board

  • greatdayforinvestments greatdayforinvestments May 18, 2009 1:04 AM Flag

    EntreMed, Inc. (Nasdaq: ENMD) Xtreme picks of the day!

    http://www1.m2.com/m2/web/story.php/2009160A6D931E1B0687802575B7005E64E2

    EntreMed, Inc. (Nasdaq: ENMD) Xtreme picks of the day!



    Published in M2 PressWIRE on Friday, 15 May 2009 at 18:23 GMT
    Copyright (C) 2009, M2 Communications Ltd.

    The team at Xtremepicks.com scans the US and Canadian markets looking for microcap companies which show promise and have unique niches and opportunities. We look at all sectors to provide investors with the best investment opportunities in search of the next multi-bagger. Join Now!

    Today's news alerts include: EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

    ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan Drug Designation

    ROCKVILLE, Md., May 15, 2009 -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical-stage drug candidates at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 - June 2, 2009 in Orlando, Florida. Presentations include both poster and discussion sessions and are listed below.

    -- Poster Session: Friday, May 29, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No.: 3520, "An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer." -- Discussion Session: Friday, May 29, 2009 - 5:00 p.m. - 5:15 p.m.

    "Angiogenesis Inhibitors: New Agents and New Combinations," Level 4, Valencia Room, W415D.

    -- Poster Session: Saturday, May 30, 2009 - 8:00 a.m. - 12:00 p.m. Abstract No.: 3562, "A single center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients with advanced cancer."

    -- Poster Session: Sunday, May 31, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No: 5577, "Phase 2 study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.